Kirchgraber Paul R's Form 4 filing
Labcorp Holdings Inc. (LH) · filed Feb 23, 2023
- Accession no.
- 0001127602-23-006642
- Filed
- Feb 23, 2023
- Trade date
- Feb 21, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kirchgraber Paul RCIK 0001791393 | Officer (CEO, Covance Drug Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 21, 2023 | Common Stock | MOption exerciseAcquired | +3,000 | $182.51 | +$547,530 | 17,069 | Direct | |
| Feb 21, 2023 | Common Stock | SSaleDisposed | −8,000 | $250.58F1 | −$2,004,640 | 9,069 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 21, 2023 | Common Stock | MOption exerciseDisposed | −3,000 | $0.00 | $0 | 4,300 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price of $250.5844 per share represents a weighted average of sales prices ranging from $250.44 to $250.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
Referenced by the price of 1 transaction in Table I.